![](https://mmo.aiircdn.com/265/659fda82881d2.jpg)
A joint clinical research by the UAE and Japan aims to offer advanced treatment options for people with diabetes.
Abu Dhabi Stem Cells Centre (ADSCC) has teamed up with Kyoto University and Japanese biotech company Rege Nephro to transform diabetes care.
Their collaborative effort focuses on creating a groundbreaking treatment using pancreatic beta cells from human induced pluripotent stem cells (iPS cells).
These cells, obtained from skin or blood, are reprogrammed (genetically modified) in highly advanced laboratories to create cells replicating the tissue affected by diabetes.
To facilitate this research mission, an ADSCC laboratory has been launched at the premises of Kyoto University in Japan.
The aim is to develop more effective therapies for type 1 diabetes and explore innovative approaches for managing type 2 diabetes by screening and testing potential drugs.
.@adsccae has partnered with biotech company Rege Nephro and Kyoto University’s Center for iPS Cell Research and Application to develop innovative diabetes treatment, utilising genetically modified and reprogrammed human skin and blood cells. pic.twitter.com/gcyWPEr6Gy
— مكتب أبوظبي الإعلامي (@ADMediaOffice) January 11, 2024